<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571558</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00842</org_study_id>
    <secondary_id>NCI-2009-00842</secondary_id>
    <secondary_id>CDR0000579270</secondary_id>
    <secondary_id>NU-NWU05-5-01</secondary_id>
    <secondary_id>NWU05-5-01</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <nct_id>NCT00571558</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia</brief_title>
  <official_title>Phase I Study of Photodynamic Therapy Using Pulsed Dye Laser and Oral Aminolevulinic Acid in Patients With Oral Leukoplakia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of photodynamic therapy using&#xD;
      aminolevulinic acid in treating patients with oral leukoplakia. Photodynamic therapy uses a&#xD;
      drug, such as aminolevulinic acid, that becomes active when it is exposed to a certain kind&#xD;
      of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using&#xD;
      aminolevulinic acid may be effective against oral leukoplakia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the toxicity and feasibility of photodynamic therapy using pulsed laser&#xD;
      therapy and oral aminolevulinic acid in treating patients with oral leukoplakia.&#xD;
&#xD;
      II. To define the dose-limiting toxicity and maximum tolerated dose of photodynamic therapy&#xD;
      using pulsed laser therapy and oral aminolevulinic acid in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the efficacy of photodynamic therapy using pulsed dye laser and oral&#xD;
      aminolevulinic acid by examining clinical response at 1 and 3 months.&#xD;
&#xD;
      II. To determine quantitative histologic response at 3 months. III. To explore the&#xD;
      association of response with specific molecular and biologic markers (i.e., DNA ploidy,&#xD;
      proliferation using Ki-67, apoptosis using TUNEL, cyclin D1, and p53).&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of long pulsed dye laser light.&#xD;
&#xD;
      Patients receive aminolevulinic acid* orally (PO) 3-4 hours before undergoing photodynamic&#xD;
      therapy using pulsed dye laser on day 1.&#xD;
&#xD;
      (Note: *Patients in cohort 1 and a latter cohort [to be determined during the course of the&#xD;
      study] do not receive aminolevulinic acid before photodynamic therapy.)&#xD;
&#xD;
      Patients undergo biopsies of target lesions and clinically uninvolved mucosa 4-8 weeks before&#xD;
      beginning therapy and then at 3 months for biomarker studies (DNA ploidy, p53, Ki-67, cyclin&#xD;
      D1, and TUNEL assay). Blood is collected on days 1, 2, 14, 28, and 84 for toxicity&#xD;
      assessment.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 84 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability with determination of optimal light dosing regimen, determination of dose limiting-toxicities, and maximum tolerated dose of photodynamic therapy using pulsed laser therapy and oral aminolevulinic acid</measure>
    <time_frame>Up to 84 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic response</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal risk marker modulation as measured by proliferation using Ki-67, apoptosis using TUNEL, cyclin D1, p53 expression, and DNA ploidy</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Oral Leukoplakia</condition>
  <arm_group>
    <arm_group_label>Treatment (aminolevulinin acid and photodynamic therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive aminolevulinic acid PO 3-4 hours before undergoing photodynamic therapy using pulsed dye laser on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminolevulinic acid hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (aminolevulinin acid and photodynamic therapy)</arm_group_label>
    <other_name>5-ALA HCl</other_name>
    <other_name>ALA HCl</other_name>
    <other_name>aminolevulinic acid HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>photodynamic therapy</intervention_name>
    <description>Undergo photodynamic therapy</description>
    <arm_group_label>Treatment (aminolevulinin acid and photodynamic therapy)</arm_group_label>
    <other_name>Light Infusion Therapyâ„¢</other_name>
    <other_name>PDT</other_name>
    <other_name>therapy, photodynamic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (aminolevulinin acid and photodynamic therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
          -  Histologically confirmed oral leukoplakia with dysplasia OR oral leukoplakia with&#xD;
             hyperplasia in a high-risk area (e.g., floor of mouth, tongue, or oropharynx)&#xD;
&#xD;
          -  Multiple oral leukoplakia lesions are allowed however no more than 5 distinct lesions&#xD;
             are biopsied and treated&#xD;
&#xD;
          -  All lesions to be treated must be technically accessible by laser&#xD;
&#xD;
          -  Patients with oral leukoplakia with hyperplasia in a non-high-risk location (e.g.,&#xD;
             buccal mucosa from ill-fitting dentures) are not allowed&#xD;
&#xD;
          -  Must be willing to undergo baseline biopsies of leukoplakia lesion(s) and surrounding&#xD;
             normal tissue 4-8 weeks before therapy and repeat biopsies at 3 months&#xD;
&#xD;
          -  No evidence of ongoing radiation damage to the target site&#xD;
&#xD;
          -  Karnofsky performance status (PS) 70-100% or Zubrod PS 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 2 years&#xD;
&#xD;
          -  Hemoglobin &gt; 12 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  ANC &gt; 1,500/mm^3&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  SGPT and SGOT =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN (a higher level of bilirubin due to a familial metabolism&#xD;
             will be considered on an individual basis)&#xD;
&#xD;
          -  Willing to adhere to avoidance of sunlight and indoor light exposure for 24 hours&#xD;
             after treatment&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to aminolevulinic acid&#xD;
&#xD;
          -  No porphyria&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situation that, in the opinion of the&#xD;
                  investigators, would limit compliance or jeopardize the patient or integrity of&#xD;
                  the data&#xD;
&#xD;
          -  Prior treatment for leukoplakia allowed&#xD;
&#xD;
          -  No prior photodynamic therapy&#xD;
&#xD;
          -  More than 3 months since prior participation in a clinical trial for leukoplakia&#xD;
&#xD;
          -  More than 4 weeks since prior ablative therapy to the target lesion&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent psoralen or PUVA therapy&#xD;
&#xD;
          -  No concurrent oral retinoids (e.g., isotretinoin)&#xD;
&#xD;
          -  No concurrent use of tanning beds&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Patients with a previous diagnosis of stage I or II head and neck cancer are eligible&#xD;
             provided definitive therapy, including radiation therapy, is completed and the patient&#xD;
             has been rendered disease free for &gt;= 2 years&#xD;
&#xD;
          -  No chronic liver disease including those with normal liver function tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wong Stuart</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Leukoplakia, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

